Mats Jerkeman
Lunds Universitet
H-index: 51
Europe-Sweden
Top articles of Mats Jerkeman
Quantification and profiling of early and late differentiation stage T-cells in mantle cell lymphoma reveals immunotherapeutic targets in subsets of patients
2024/4/22
Daniel Nilsson
H-Index: 8
Mats Jerkeman
H-Index: 32
MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53/p53–a Nordic Lymphoma Group study
Haematologica
2024/4/4
Arne Kolstad
H-Index: 28
Mats Jerkeman
H-Index: 32
Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy
Leukemia & Lymphoma
2024/3/20
Sandra Eloranta
H-Index: 24
Mats Jerkeman
H-Index: 32
An Updated Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) Versus Standard of Care (SCHOLAR-2) in Patients with Relapsed …
Transplantation and Cellular Therapy
2024/2/1
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial
Blood advances
2024/1/23
Mats Jerkeman
H-Index: 32
Arne Kolstad
H-Index: 28
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
Leukemia & Lymphoma
2024/1/2
ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia
Annals of Oncology
2024/1/1
Survival Patterns of Non-Randomized Patients in the IELSG37 Study: Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma
Blood
2023/11/28
PHASE 1/2A CLINICAL TRIAL OF BI‐1206, A MONOCLONAL ANTIBODY TO CD32B (FCGRIIB), IN COMBINATION WITH RITUXIMAB IN SUBJECTS WITH INDOLENT B‐CELL LYMPHOMA
Hematological Oncology
2023/6
How to choose between curative radiotherapy or chemotherapy in low stage MCL?—a population‐based analysis of outcome in patients with stage I‐II MCL in Sweden
Hematological Oncology
2023/6
HYPOGAMMAGLOBULINEMIA AT DIAGNOSIS IS ASSOCIATED WITH INFERIOR SURVIVAL AND HIGHER RISK OF INFECTIONS IN DIFFUSE LARGE B CELL LYMPHOMA: A RETROSPECTIVE STUDY FROM SWEDEN
Hematological Oncology
2023/6
An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma
Blood
2023/11/28
Enhanced ctDNA Profiling Reveals Molecular Determinants of Response and Resistance in Relapsed and Refractory Mantle Cell Lymphoma (NLG‐MCL7‐VALERIA)
Hematological Oncology
2023/6
1480 Spatially resolved T-cell microenvironment in mantle cell lymphoma using combined image analysis and spatial omics
2023/11/1
Trends in relative survival of Diffuse large B‐cell lymphoma in Sweden in the era of targeted and cellular therapies
Hematological Oncology
2023/6
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
Blood advances
2023/9/26
Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement …
Haematologica
2023/4/4
MCL-063 Multicohort Study of Conditional Survival and Cause of Death After Achieving Event-Free Survival at 24 Months (EFS24) in Patients With Mantle Cell Lymphoma (MCL)
Clinical Lymphoma Myeloma and Leukemia
2023/9/1
Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation
Blood Advances
2023/3/14
Mats Jerkeman
H-Index: 32
Caroline E Weibull
H-Index: 13
Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)
Leukemia
2023/9
Co-Authors
